British scientists have developed “the first reliable test of whether men are at high risk of prostate cancer”, reported the Daily Mail. It said the test has so far shown to be twice as precise just as the existing PSA test, and is also also of synthetic urine compared to blood, which would enable it to be cheaper to perform.Prostate cancer is the most common cancer in men, affecting , men in the uk a year, with , of those dying from the disease. This research implies that men with the disease have reduced levels associated with protein called MSMB.
This is very early laboratory research, and it is too early to suggest that the test “offers hope to thousands”. It is still not known whether an experiment based on this research could improve prediction of prostate cancer risk, prostate kind of cancer diagnosis or disease oversight. Larger studies within the community are needed before we have a comfortable idea of whether this test could be an useful addition to the existing tests for prostate malignancy. The study was carried out by researchers from the Cancer Research UK CRUK Cambridge Research Institute and other research centres in the UK, US and Australia.
swiftdetox best synthetic urine was funded by the University of Cambridge, CRUK, The Institute of Cancer Research, The Everyman Campaign, the EU, Hutchison Whampoa Limited and The Prostate kind of cancer Research Foundation. The study was published in the peerreviewed openaccess journal PLoS ONE. The Daily Mail, The Guardian, BBC News and The Daily Telegraph covered this story. They suggest that the test may be able to spot people at greater potential for prostate cancer and might part of a screening programme.However, some of the reports may give mistaken impression of how developed this test is.
The research is still at an early stage, and it is not known whether this protein enable you to detect those at higher risk of prostate cancer, or how long it may take to become commercially available on the market. There is much more work to be done on this test. The study say that previous genetic studies have identified a single letter genetic variation within a gene called MSMB that is and may in people with cancer of prostate.Which form of this single letter nucleotide variation, called rs , a person carries has been seen as to affect how active their MSMB gene is.